{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T08:31:43Z","timestamp":1791102703226,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2005,12,1]]},"DOI":"10.1038\/ncponc0351","type":"journal-article","created":{"date-parts":[[2005,12,12]],"date-time":"2005-12-12T15:09:15Z","timestamp":1134400155000},"page":"S36-S44","source":"Crossref","is-referenced-by-count":54,"title":["Inhibitors of DNA methylation: beyond myelodysplastic syndromes"],"prefix":"10.1038","volume":"2","author":[{"given":"Pierre","family":"Fenaux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncponc0351_CR1","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1135\/cccc19642060","volume":"29","author":"A Piskala","year":"1964","unstructured":"Piskala A et al. (1964) Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine. Collect Czech Chem Commun 29: 2060\u20132076","journal-title":"Collect Czech Chem Commun"},{"key":"BFncponc0351_CR2","first-page":"619","volume":"6","author":"LJ Hanka","year":"1966","unstructured":"Hanka LJ et al. (1966) Microbiological production of 5-azacytidine. I. Production and biological activity. Antimicrob Agents Chemother 6: 619\u2013624","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"BFncponc0351_CR3","first-page":"21","volume":"7","author":"LR Silverman","year":"1993","unstructured":"Silverman LR et al. (1993) Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (Suppl 1): 21\u201329","journal-title":"Leukemia"},{"key":"BFncponc0351_CR4","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 20: 2429\u20132440","journal-title":"J Clin Oncol"},{"key":"BFncponc0351_CR5","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","volume":"20","author":"AB Kornblith","year":"2002","unstructured":"Kornblith AB et al. (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20: 2441\u20132452","journal-title":"J Clin Oncol"},{"key":"BFncponc0351_CR6","unstructured":"Pharmion Corporation. (2004) Vidaza\u00ae (azacitidine, injectable, subcutaneous) package insert; Pharmion, Boulder, CO, USA."},{"key":"BFncponc0351_CR7","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/5947","volume":"21","author":"PA Jones","year":"1999","unstructured":"Jones PA and Laird PW (1999) Cancer epigenetics comes of age. Nat Genet 21: 163\u2013167","journal-title":"Nat Genet"},{"key":"BFncponc0351_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00277-003-0650-0","volume":"82","author":"B Behringer","year":"2003","unstructured":"Behringer B et al. (2003) Prognosis of older patients with acute myeloid leukemia receiving either inducion or noncurative treatment: a single-center retrospective study. Ann Hematol 82: 381\u2013389","journal-title":"Ann Hematol"},{"key":"BFncponc0351_CR9","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","volume":"89","author":"CP Leith","year":"1997","unstructured":"Leith CP et al. (1997) Acute myeloid leukemia in the elderly: assessment of multi-drug resistance (MDR) and cytogenetics distinguishes biological subgroups with remarkably distinct responses to standard chemotherapy: a Southwest oncology group study. Blood 89: 3323\u20133329","journal-title":"Blood"},{"key":"BFncponc0351_CR10","doi-asserted-by":"crossref","unstructured":"Stone RM et al. Acute myeloid leukemia. In American Society of Hematology Education Program Book: 2004 December 4\u20137; San Diego, 98\u2013117 (Eds Broudy VC et al.) Washington, DC: American Society of Hematology","DOI":"10.1182\/asheducation-2004.1.98"},{"key":"BFncponc0351_CR11","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M et al. (2005) The develoment of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640\u20132653","journal-title":"Blood"},{"key":"BFncponc0351_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.hoc.2004.03.001","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A et al. (2004) Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin N Am 18: 641\u2013656","journal-title":"Hematol Oncol Clin N Am"},{"key":"BFncponc0351_CR13","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1200\/JCO.1998.16.9.2897","volume":"16","author":"SJ Lee","year":"1998","unstructured":"Lee SJ et al. (1998) Initial therapy for chronic myelogenous leukemia: playing the odds. J Clin Oncol 16: 2897\u20132903","journal-title":"J Clin Oncol"},{"key":"BFncponc0351_CR14","first-page":"1649","volume":"8","author":"HM Ghaddar","year":"1994","unstructured":"Ghaddar HM et al. (1994) Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two disease states. Leukemia 8: 1649\u20131653","journal-title":"Leukemia"},{"key":"BFncponc0351_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0168-9525(99)01971-X","volume":"16","author":"SB Baylin","year":"2000","unstructured":"Baylin SB and Herman JG (2000) DNA hypermethylation in tumorigenesis. Trends Genet 16: 168\u2013174","journal-title":"Trends Genet"},{"key":"BFncponc0351_CR16","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1038\/sj.onc.1204341","volume":"20","author":"KD Robertson","year":"2001","unstructured":"Robertson KD (2001) DNA methylation, methyltransferases, and cancer. Oncogene 20: 3139\u20133155","journal-title":"Oncogene"},{"key":"BFncponc0351_CR17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/jmg.38.5.285","volume":"38","author":"JF Costello","year":"2001","unstructured":"Costello JF and Plass C (2001) Methylation matters. J Med Genet 38: 285\u2013303","journal-title":"J Med Genet"},{"key":"BFncponc0351_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0022-2836(88)90122-2","volume":"203","author":"T Bestor","year":"1988","unstructured":"Bestor T et al. (1988) Cloning and sequencing of a cDNA encoding DNA methyltransferase of mouse cells. The carboxyl-terminal domain of the mammalian enzymes is related to bacterial restriction methyltransferases. J Mol Biol 203: 971\u2013983","journal-title":"J Mol Biol"},{"key":"BFncponc0351_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","volume":"99","author":"M Okano","year":"1999","unstructured":"Okano M et al. (1999) DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99: 247\u2013257","journal-title":"Cell"},{"issue":"Suppl 1","key":"BFncponc0351_CR20","first-page":"7","volume":"11","author":"J-P Issa","year":"1997","unstructured":"Issa J-P et al. (1997) DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia 11 (Suppl 1): 7\u201311","journal-title":"Leukemia"},{"key":"BFncponc0351_CR21","first-page":"3730","volume":"59","author":"JR Melki","year":"1999","unstructured":"Melki JR et al. (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59: 3730\u20133740","journal-title":"Cancer Res"},{"key":"BFncponc0351_CR22","first-page":"722","volume":"56","author":"JG Herman","year":"1996","unstructured":"Herman JG et al. (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res 56: 722\u2013777","journal-title":"Cancer Res"},{"key":"BFncponc0351_CR23","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1182\/blood.V95.9.2990.009k08_2990_2992","volume":"95","author":"TT Nguyen","year":"2000","unstructured":"Nguyen TT et al. (2000) Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood 95: 2990\u20132992","journal-title":"Blood"},{"key":"BFncponc0351_CR24","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/blood.V70.2.412.412","volume":"70","author":"SB Baylin","year":"1987","unstructured":"Baylin SB et al. (1987) Hypermethylation of the 5' region of the calcitonin gene is a property of human lymphoid and acute myeloid malignancies. Blood 70: 412\u2013417","journal-title":"Blood"},{"key":"BFncponc0351_CR25","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1182\/blood.V77.11.2435.bloodjournal77112435","volume":"77","author":"T Malinen","year":"1991","unstructured":"Malinen T et al. (1991) Acceleration of chronic myeloid leukemia correlates with calcitonin gene hypermethylation. Blood 77: 2435\u20132440","journal-title":"Blood"},{"key":"BFncponc0351_CR26","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood.V99.7.2291","volume":"99","author":"J Roman-Gomez","year":"2002","unstructured":"Roman-Gomez J et al. (2002) 5' CpG Island hypermethylation is associated with transcription silencing of the p21 CIPI\/WAFI\/SDI1 gene and confers poor prognosis in acute lymphobalstic leukemia. Blood 99: 2291\u20132296","journal-title":"Blood"},{"key":"BFncponc0351_CR27","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","volume":"21","author":"JK Christman","year":"2002","unstructured":"Christman JK (2002) 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483\u20135495","journal-title":"Oncogene"},{"key":"BFncponc0351_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1054-3589(08)60190-8","volume":"14","author":"DD Von Hoff","year":"1977","unstructured":"Von Hoff DD and Slavik M (1977) 5-azacytidine\u2014a new anticancer drug with significant activity in acute myeloblastic leukemia. Adv Pharmacol Chemother 14: 285\u2013326","journal-title":"Adv Pharmacol Chemother"},{"key":"BFncponc0351_CR29","first-page":"319","volume":"57","author":"KB McCredie","year":"1973","unstructured":"McCredie KB et al. (1973) Treatment of acute leukemia with 5-azacytidine (NSC-102816). Cancer Chemother Rep 57: 319\u2013323","journal-title":"Cancer Chemother Rep"},{"key":"BFncponc0351_CR30","first-page":"97","volume":"14","author":"C Tan","year":"1973","unstructured":"Tan C et al. (1973) Clinical trial of 5-azacytidine (5-azaCR) [abstract]. Cancer Res 14: 97","journal-title":"Cancer Res"},{"key":"BFncponc0351_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.V42.3.359.359","volume":"42","author":"M Karon","year":"1973","unstructured":"Karon M et al. (1973) 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 42: 359\u2013365","journal-title":"Blood"},{"key":"BFncponc0351_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.7326\/0003-4819-85-2-237","volume":"85","author":"DD Von Hoff","year":"1976","unstructured":"Von Hoff DD et al. (1976) 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 85: 237\u2013245","journal-title":"Ann Intern Med"},{"key":"BFncponc0351_CR33","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood.V48.3.331.331","volume":"48","author":"WR Vogler","year":"1976","unstructured":"Vogler WR et al. (1976) 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood 48: 331\u2013337","journal-title":"Blood"},{"key":"BFncponc0351_CR34","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/1097-0142(19810401)47:7<1739::AID-CNCR2820470702>3.0.CO;2-2","volume":"47","author":"JH Saiki","year":"1981","unstructured":"Saiki JH et al. (1981) Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: a Southwest Oncology Group Study. Cancer 47: 1739\u20131742","journal-title":"Cancer"},{"key":"BFncponc0351_CR35","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000225641","volume":"39","author":"DC Case Jr","year":"1982","unstructured":"Case DC Jr (1982) 5-azacytidine in refractory acute leukemia. Oncology 39: 218\u2013221","journal-title":"Oncology"},{"key":"BFncponc0351_CR36","first-page":"807","volume":"69","author":"EF Winton","year":"1985","unstructured":"Winton EF et al. (1985) Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group. Cancer Treat Rep 69: 807\u2013811","journal-title":"Cancer Treat Rep"},{"key":"BFncponc0351_CR37","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1200\/JCO.1987.5.7.1022","volume":"5","author":"N Hakami","year":"1987","unstructured":"Hakami N et al. (1987) Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 5: 1022\u20131025","journal-title":"J Clin Oncol"},{"key":"BFncponc0351_CR38","first-page":"835","volume":"4","author":"EJ Lee","year":"1990","unstructured":"Lee EJ et al. (1990) Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. Leukemia 4: 835\u2013838","journal-title":"Leukemia"},{"key":"BFncponc0351_CR39","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ajh.2830430411","volume":"43","author":"J Goldberg","year":"1993","unstructured":"Goldberg J et al. (1993) Mitoxantrone and 5-azacytidine for refractory\/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. Am J Hematol 43: 286\u2013290","journal-title":"Am J Hematol"},{"key":"BFncponc0351_CR40","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1200\/JCO.1996.14.5.1521","volume":"14","author":"CP Steuber","year":"1996","unstructured":"Steuber CP et al. (1996) Induction treatment of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 14: 1521\u20131525","journal-title":"J Clin Oncol"},{"key":"BFncponc0351_CR41","first-page":"C-748","volume":"20","author":"D Oblon","year":"1984","unstructured":"Oblon D et al. (1984) Long-term follow up of brief, intensive chemotherapy without maintenance therapy for acute myelogenous leukemia (AML): A SECSG pilot study [abstract]. Proc Am Soc Clin Oncol 20: C-748","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 2","key":"BFncponc0351_CR42","first-page":"48","volume":"6","author":"HE Grier","year":"1992","unstructured":"Grier HE et al. (1992) Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia 6 (Suppl 2): 48\u201351","journal-title":"Leukemia"},{"key":"BFncponc0351_CR43","first-page":"499a","volume-title":"Meeting Abstracts of the American Society of Hematology: 2004 December 5; San Diego http:\/\/www.abstracts2view.com\/hem_sandiego2004\/view.php?nu=HEM4L1_4764] (accessed 28 September 2005); also Blood","author":"RK Shadduck","year":"2004","unstructured":"Shadduck RK et al. (2004) AML induction therapy with outpatient azacitidine [abstract #1800]. In Meeting Abstracts of the American Society of Hematology: 2004 December 5; San Diego \n                      http:\/\/www.abstracts2view.com\/hem_sandiego2004\/view.php?nu=HEM4L1_4764\n                    ] (accessed 28 September 2005); also Blood 104 (Suppl 1): 499a"},{"key":"BFncponc0351_CR44","first-page":"267","volume":"66","author":"CA Schiffer","year":"1982","unstructured":"Schiffer CA et al. (1982) Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Cancer Treat Rep 66: 267\u2013271","journal-title":"Cancer Treat Rep"},{"key":"BFncponc0351_CR45","first-page":"770","volume":"6","author":"JP Dutcher","year":"1992","unstructured":"Dutcher JP et al. (1992) Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 6: 770\u2013775","journal-title":"Leukemia"},{"key":"BFncponc0351_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/0145-2126(81)90116-8","volume":"5","author":"GE Rivard","year":"1981","unstructured":"Rivard GE et al. (1981) Phase I study on 5-Aza-2'-deoxycytidine in children with acute leukemia. Leukemia Res 5: 453\u2013462","journal-title":"Leukemia Res"},{"key":"BFncponc0351_CR47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0163-7258(85)90052-X","volume":"30","author":"RL Momparler","year":"1985","unstructured":"Momparler RL et al. (1985) Clinical trial on 5-aza-2'-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30: 277\u2013286","journal-title":"Pharmacol Ther"},{"key":"BFncponc0351_CR48","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/bjc.1991.258","volume":"64","author":"DJ Richel","year":"1991","unstructured":"Richel DJ et al. (1991) The antileukemic activity of 5-aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br J Cancer 64: 144\u2013148","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"BFncponc0351_CR49","first-page":"36","volume":"7","author":"AC Petti","year":"1993","unstructured":"Petti AC et al. (1993) Pilot study of 5-aza-2'-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7 (Suppl 1): 36\u201341","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"BFncponc0351_CR50","first-page":"28","volume":"11","author":"G Schwartsmann","year":"1997","unstructured":"Schwartsmann G et al. (1997) Decitabine (5-Aza-2-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. Leukemia 11 (Suppl 1): 28\u201331","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"BFncponc0351_CR51","first-page":"24","volume":"11","author":"R Willemze","year":"1997","unstructured":"Willemze R et al. (1997) A randomized phase II study on the effects of 5-aza-2' deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). Leukemia 11 (Suppl 1): 24\u201327","journal-title":"Leukemia"},{"key":"BFncponc0351_CR52","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/sj.leu.2400796","volume":"11","author":"HM Kantarjian","year":"1997","unstructured":"Kantarjian HM et al. (1997) Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11: 1617\u20131620","journal-title":"Leukemia"},{"key":"BFncponc0351_CR53","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","volume":"86","author":"S Sacchi","year":"1999","unstructured":"Sacchi S et al. (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 86: 2632\u20132641","journal-title":"Cancer"},{"key":"BFncponc0351_CR54","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"P Wijermans","year":"2000","unstructured":"Wijermans P et al. (2000) Low-dose 5-aza-2' deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multi-center phase II study in elderly patients. J Clin Oncol 18: 956\u2013962","journal-title":"J Clin Oncol"},{"key":"BFncponc0351_CR55","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","volume":"103","author":"JJ Issa","year":"2004","unstructured":"Issa JJ et al. (2004) Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2' deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635\u20131640","journal-title":"Blood"},{"key":"BFncponc0351_CR56","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/cncr.11543","volume":"98","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM et al. (2003) Results of decitabine (5-aza-2' deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98: 522\u2013528","journal-title":"Cancer"},{"key":"BFncponc0351_CR57","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/cncr.11184","volume":"97","author":"M de Lima","year":"2003","unstructured":"de Lima M et al. (2003) Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97: 1242\u20131247","journal-title":"Cancer"},{"key":"BFncponc0351_CR58","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/sj.bmt.1703028","volume":"27","author":"F Ravandi","year":"2001","unstructured":"Ravandi F et al. (2001) Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant 27: 1221\u20131225","journal-title":"Bone Marrow Transplant"},{"key":"BFncponc0351_CR59","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199602)51:2<117::AID-AJH4>3.0.CO;2-0","volume":"5","author":"AD Kritz","year":"1996","unstructured":"Kritz AD et al. (1996) Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed\/refractory leukemia. Am J Hematol 5: 117\u2013121","journal-title":"Am J Hematol"},{"key":"BFncponc0351_CR60","first-page":"460a","volume":"98","author":"LH Camacho","year":"2001","unstructured":"Camacho LH et al. (2001) Transcription modulation: a pilot study of sodium phenylbutyrate plus 5-azacytidine [abstract]. Blood 98: 460a","journal-title":"Blood"},{"key":"BFncponc0351_CR61","doi-asserted-by":"publisher","first-page":"622a","DOI":"10.1182\/blood.V98.3.705","volume":"98","author":"CB Miller","year":"2001","unstructured":"Miller CB et al. (2001) A Phase I dose-descalation trial of combined DNA methyltransferase (MeT)\/histone deacetylase (HDAC) inhibition in myeloid malignancies [abstract]. Blood 98: 622a","journal-title":"Blood"},{"key":"BFncponc0351_CR62","first-page":"A12","volume":"68","author":"LR Silverman","year":"1994","unstructured":"Silverman LR et al. (1994) Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921 [abstract]. Am Hematol 68: A12","journal-title":"Am Hematol"},{"key":"BFncponc0351_CR63","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1158\/1078-0432.CCR-04-2135","volume":"11","author":"E Kaminskas","year":"2005","unstructured":"Kaminskas E et al. (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11: 3604\u20133608","journal-title":"Clin Cancer Res"},{"key":"BFncponc0351_CR64","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES et al. (2001) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press"},{"key":"BFncponc0351_CR65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/sj.leu.2400550","volume":"11","author":"RL Momparler","year":"1997","unstructured":"Momparler RL et al. (1997) Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia. Leukemia 11: 175\u2013180","journal-title":"Leukemia"},{"key":"BFncponc0351_CR66","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","volume":"15","author":"E Estey","year":"1997","unstructured":"Estey E et al. (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 15: 2969\u20132977","journal-title":"Blood"},{"key":"BFncponc0351_CR67","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/sj.leu.2401711","volume":"14","author":"G Rossi","year":"2000","unstructured":"Rossi G et al. (2000) Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia 14: 636\u2013641","journal-title":"Leukemia"},{"key":"BFncponc0351_CR68","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","volume":"96","author":"JE Parker","year":"2000","unstructured":"Parker JE et al. (2000) The role of apoptosis, proliferation, and the Bcl-2 related proteins in myelodysplastic syndromes and acute myeloid leukemias secondary to MDS. Blood 96: 3932\u20133938","journal-title":"Blood"},{"key":"BFncponc0351_CR69","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW et al. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292\u20132302","journal-title":"Blood"},{"key":"BFncponc0351_CR70","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.1038\/sj.onc.1206814","volume":"22","author":"R Claus","year":"2003","unstructured":"Claus R et al. (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22: 6489\u20136496","journal-title":"Oncogene"},{"key":"BFncponc0351_CR71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/25779","volume":"395","author":"RZ Chen","year":"1998","unstructured":"Chen RZ et al. (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395: 89\u201393","journal-title":"Nature"},{"key":"BFncponc0351_CR72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/jnci\/95.4.327","volume":"95","author":"N Sato","year":"2003","unstructured":"Sato N et al. (2003) Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness. J Natl Cancer Inst 95: 327\u2013330","journal-title":"J Natl Cancer Inst"},{"key":"BFncponc0351_CR73","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.1083557","volume":"300","author":"A Eden","year":"2003","unstructured":"Eden A et al. (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300: 455","journal-title":"Science"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncponc0351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0351","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T09:17:40Z","timestamp":1650100660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":73,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2005,12,1]]}},"alternative-id":["BFncponc0351"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0351","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}